Viewing data from:

ETHACRYNIC ACID

ANDA

ETHACRYNIC ACID | A205609 | ADAPTIS PHARMA PRIVATE LTD

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: EDECRIN(TE code: AB)

Medicare Part D Spending

CMS annual spending data for Ethacrynic Acid (2023)

Total Spending

$7.9M

Total Claims

13,895

Beneficiaries

3,813

Avg Cost/Unit

$5.75

Spending Trend

$9.2M(2019)→$10.1M(2020)→$10.6M(2021)→$9.9M(2022)→$7.9M(2023)

YoY Change:-18.4%

5yr CAGR:-15.7%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain10 active DMFs2 inactive

10 active API suppliers hold Drug Master Files for this ingredient.

EGIS PHARMACEUTICALS PLCETHACRYNIC ACID

DMF 171932004

ZYDUS LIFESCIENCES LTDETHACRYNIC ACID USP

DMF 256472012

TOPCHEM PHARMACEUTICALS LTDETHACRYNIC ACID

DMF 259362012

OLON SPAETHACRYNIC ACID

DMF 259732012

MATRIX PHARMACORP PRIVATE LTDETHACRYNIC ACID USP

DMF 260132012

CHEMWERTH INCETHACRYNIC ACID USP NON-STERILE BULK DRUG

DMF 263372013

BRECKENRIDGE PHARMACEUTICAL INCETHACRYNIC ACID USP

DMF 274732013

BIOPHORE INDIA PHARMACEUTICALS PVT LTDETHACRYNIC ACID

DMF 294292015

SOLARA ACTIVE PHARMA SCIENCES LTDETHACRYNIC ACID USP

DMF 320692017

EMCURE PHARMACEUTICALS LTDETHACRYNIC ACID USP

DMF 324272018

EGIS PHARMACEUTICALS PRIVATE LTDInactiveETHACRYNIC ACID

DMF 74111988

SUNNY PHARMTECH INCInactiveETHACRYNIC ACID USP

DMF 319252017

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Jul 5, 2016	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 25MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Jun 30, 2016

No patent or exclusivity listings for this strength.